Gilead Sciences (GILD) Other Non-Current Assets (2009 - 2026)
Gilead Sciences posted quarterly Other Non-Current Assets of $4.6 billion for Q1 2026, up 17.64% year-on-year from $3.9 billion in Q1 2025, and down 6.01% on a QoQ basis from $4.8 billion in Q4 2025.
Gilead Sciences (GILD) has 18 years of Other Non-Current Assets data on file, last reported at $4.6 billion in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets rose 17.64% year-over-year to $4.6 billion; the trailing twelve-month figure through Mar 2026 stood at $4.6 billion (up 17.64% YoY), and the FY2025 full-year result was $4.8 billion, up 28.55% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $4.6 billion, down from $4.8 billion in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $5.5 billion in Q3 2024 and bottomed at $3.8 billion in Q4 2024.
- The 5-year median for Other Non-Current Assets is $4.8 billion (2022), against an average of $4.7 billion.
- The widest annual swing landed in 2024, when Other Non-Current Assets surged 30.81%; it then fell 25.39% in 2025.
- A 5-year view of Other Non-Current Assets shows it stood at $4.8 billion in 2022, then declined by 0.17% to $4.8 billion in 2023, then declined by 21.35% to $3.8 billion in 2024, then grew by 28.55% to $4.8 billion in 2025, then fell by 6.01% to $4.6 billion in 2026.
- The last three Other Non-Current Assets figures came in at $4.6 billion (Q1 2026), $4.8 billion (Q4 2025), and $4.9 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | 200.00 Mn |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 7.23 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 14.11 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 10.54 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 19.81 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 12.76 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 4.55 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 9.83 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 6.08 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 2.86 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.55 Bn |
| Dec 31, 2025 | 4.85 Bn |
| Sep 30, 2025 | 4.87 Bn |
| Jun 30, 2025 | 4.03 Bn |
| Mar 31, 2025 | 3.87 Bn |
| Dec 31, 2024 | 3.77 Bn |
| Sep 30, 2024 | 5.49 Bn |
| Jun 30, 2024 | 4.77 Bn |
| Mar 31, 2024 | 5.19 Bn |
| Dec 31, 2023 | 4.79 Bn |
| Sep 30, 2023 | 4.20 Bn |
| Jun 30, 2023 | 5.11 Bn |
| Mar 31, 2023 | 4.95 Bn |
| Dec 31, 2022 | 4.80 Bn |
| Sep 30, 2022 | 4.62 Bn |
| Jun 30, 2022 | 4.86 Bn |
| Mar 31, 2022 | 5.13 Bn |
| Dec 31, 2021 | 4.96 Bn |
| Sep 30, 2021 | 4.74 Bn |
| Jun 30, 2021 | 5.55 Bn |
| Mar 31, 2021 | 5.53 Bn |
| Dec 31, 2020 | 5.71 Bn |
| Sep 30, 2020 | 6.01 Bn |
| Jun 30, 2020 | 7.02 Bn |
| Mar 31, 2020 | 7.08 Bn |
| Dec 31, 2019 | 7.44 Bn |
| Sep 30, 2019 | 5.23 Bn |
| Jun 30, 2019 | 2.91 Bn |
| Mar 31, 2019 | 2.92 Bn |
| Dec 31, 2018 | 2.56 Bn |
| Sep 30, 2018 | 2.79 Bn |
| Jun 30, 2018 | 2.61 Bn |
| Mar 31, 2018 | 2.64 Bn |
| Dec 31, 2017 | 2.72 Bn |
| Sep 30, 2017 | 2.61 Bn |
| Jun 30, 2017 | 2.32 Bn |
| Mar 31, 2017 | 2.31 Bn |
| Dec 31, 2016 | 3.90 Bn |
| Sep 30, 2016 | 1.65 Bn |
| Jun 30, 2016 | 1.48 Bn |
| Mar 31, 2016 | 383.00 Mn |
| Dec 31, 2015 | 934.00 Mn |
| Sep 30, 2015 | 409.00 Mn |
| Jun 30, 2015 | 682.00 Mn |
| Mar 31, 2015 | 447.00 Mn |
| Dec 31, 2014 | 731.00 Mn |
| Sep 30, 2014 | 487.85 Mn |
| Jun 30, 2014 | 497.50 Mn |
| Mar 31, 2014 | 191.35 Mn |
| Dec 31, 2013 | 519.00 Mn |
| Sep 30, 2013 | 177.45 Mn |
| Jun 30, 2013 | 183.66 Mn |
| Mar 31, 2013 | 149.95 Mn |
| Dec 31, 2012 | 159.19 Mn |
| Sep 30, 2012 | 170.63 Mn |
| Jun 30, 2012 | 171.28 Mn |
| Mar 31, 2012 | 169.84 Mn |
| Dec 31, 2011 | 174.58 Mn |
| Sep 30, 2011 | 131.65 Mn |
| Jun 30, 2011 | 189.27 Mn |
| Mar 31, 2011 | 197.00 Mn |
| Dec 31, 2010 | 181.15 Mn |
| Sep 30, 2010 | 111.95 Mn |
| Mar 31, 2010 | 219.19 Mn |
| Dec 31, 2009 | 226.25 Mn |
| Sep 30, 2009 | 79.21 Mn |
| Jun 30, 2009 | 89.98 Mn |